| Autor: |
Tracy, Michaela S., Duncan, Daniel R., Rosen, Rachel L. |
| Předmět: |
|
| Zdroj: |
Acta Paediatrica; Feb2022, Vol. 111 Issue 2, p440-441, 2p |
| Abstrakt: |
Abbreviations GERD Gastroesophageal reflux disease GI Gastroenterology H2RA H2 antagonist PCP Primary care physician PPI Proton pump inhibitor Many infants with fussiness or spitting-up are prescribed acid suppression therapy with proton pump inhibitors (PPIs) and H2 antagonists (H2RAs) despite data suggesting these therapies do not improve symptoms over placebo.1,2 Furthermore, there are risks with acid suppression treatment, including increasing rates of gastroenteritis, pneumonia and necrotising enterocolitis.3 In 2018, the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) and the European Society of Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) released updated clinical practice guidelines for the management of gastroesophageal reflux disease (GERD) for infants.4 The guidelines recommend thickening and trial of hypoallergenic formula as first-line therapies for the treatment of GERD in infants, as well as referral to gastroenterology (GI) clinician prior to starting acid suppression. Also, the patients in this study had severe enough symptoms to require referral to GI clinic; thus, our data does not capture changes made by primary care providers for patients who had symptom resolution. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text